SCHEMBL5863427

SCHEMBL5863427

CCNC(=O)C1(CCCN2CCN(c3ccc4c(c3)C(=O)N(Cc3cccc(Cl)c3)CC4)CC2)c2ccccc2Sc2ccccc21

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR7 P34969 5/20 0.41
KDM4E B2RXH2 2/20 0.40
MEN1 O00255 2/20 0.40
LMNA P02545 2/20 0.40
HTT P42858 2/20 0.40
KMT2A Q03164 2/20 0.40
RAD52 P43351 1/20 0.40
DRD2 P14416 4/20 0.39
DRD4 P21917 2/20 0.39
DRD1 P21728 1/20 0.39
DRD3 P35462 1/20 0.39
SIGMAR1 Q99720 1/20 0.38
HTR2A P28223 2/20 0.38
HTR2C P28335 1/20 0.38
SLC6A4 P31645 1/20 0.38
MAPT P10636 2/20 0.38
HTR1A P08908 1/20 0.37
HTR6 P50406 1/20 0.37
POLB P06746 1/20 0.37
IDE P14735 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5863901 0.98 HTR7 (0.42) HTR7KDM4EMEN1LMNAHTT
SCHEMBL5864255 0.94 DRD3 (0.40) HTR7KDM4EDRD2DRD4DRD1
SCHEMBL5864030 0.94 HTR7 (0.42) HTR7KDM4EMEN1LMNAHTT
SCHEMBL5864096 0.93 HTR7 (0.43) HTR7DRD2DRD4DRD1DRD3
SCHEMBL5863395 0.92 LMNA (0.43) KDM4EMEN1LMNAHTTKMT2A
SCHEMBL5864275 0.92 DRD3 (0.41) HTR7DRD2DRD4DRD1DRD3
SCHEMBL5863993 0.92 ATM (0.41) HTR7KDM4EMEN1LMNAHTT
SCHEMBL5864088 0.92 HTR7 (0.42) HTR7KDM4EMEN1LMNAHTT
SCHEMBL5864302 0.91 DRD1 (0.40) HTR7KDM4EMEN1LMNAHTT
SCHEMBL6891623 0.91 HTR7 (0.42) HTR7DRD2DRD4DRD1DRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7030120-B2 Nitrogen-containing heterocyclic compounds and benzamide compounds and drugs containing the same MEIJI SEIKA KAISHA, LTD. (JP) 2006-04-18 US disclosed
US-20040224959-A1 Nitrogen-containing heterocyclic compounds and benzamide compounds and drugs containing the same OHKURA NAOTO (JP) 2004-11-11 US disclosed
US-6777414-B1 INHIBITORS OF TRIGLYCERIDE BIOSYNTHESIS AND SECRETION OF APOLIPOPROTEIN B-CONTAINING LIPOPROTEINS; ARTERIOSCLEROTIC DISEASES; HYPERLIPIDEMIA MEIJI SEIKA KAISHA, LTD. (JP) 2004-08-17 US disclosed
EP-1180514-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND BENAMIDE COMPOUNDS AND DRUGS CONTAINING THE SAME MEIJI SEIKA KAISHA LTD. (JP) 2002-02-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040224959-A1 Nitrogen-containing heterocyclic compounds and benzamide compounds and drugs containing the same APOB, NCEH1, LIPC HTR7 1820/4885KDM4E 2536/4885MEN1 4072/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.